Tumor Innate Immune Surveillance

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (31 January 2021) | Viewed by 2757

Special Issue Editor


E-Mail Website
Guest Editor
Cancer Research Center Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, 28 rue Laennec, 69373 Lyon, France
Interests: tumor immune surveillance; dendritic cells; neutrophils; regulatory T cells; effector T cells; immunotherapies; innate sensors

Special Issue Information

Dear Colleagues,

Key immune evasion mechanisms in established tumors have been well characterized, culminating with the clinical approval of several drugs targeting T cell immune checkpoints (ICP). By contrast, while the concept of tumor immune surveillance is well accepted, the very early events that permit immune sensing of pre-neoplastic cells remain poorly understood. The objective of this Special Issue is to gather original studies and reviews addressing immune sensing mechanisms of early cell transformation. The Special Issue is expected to assemble studies analyzing interactions between cells undergoing transformation and innate immune cells based on in vitro and/or in vivo models. Studies on conventional T/B cells are out of the scope of this Special Issue. Of specific interest are studies deciphering the role in the detection of early cell transformation of specific immune cell types, such as dendritic cells, macrophages, neutrophils, and other myeloid cells, and of innate lymphoid cells, including unconventional T cells (NKT, gdT cells) and NK cells. Further, studies deciphering tumor intrinsic molecular mechanisms (i.e., senescence, cellular stresses such as the UPR, Genomic stress) or intracellular sensors (Sting, RIG-I, etc.) leading to early immune alert are welcome.

Dr. Christophe Caux
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tumor immune surveillance
  • Innate immune sensing
  • dendritic cells
  • myeloid cells
  • innate lymphoid cells
  • cellular stresses

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 30574 KiB  
Article
Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast Cancer
by Florence Boissière-Michot, Ghita Chabab, Caroline Mollevi, Séverine Guiu, Evelyne Lopez-Crapez, Jeanne Ramos, Nathalie Bonnefoy, Virginie Lafont and William Jacot
Cancers 2021, 13(4), 765; https://doi.org/10.3390/cancers13040765 - 12 Feb 2021
Cited by 14 | Viewed by 2120
Abstract
The prognostic impact of the different tumor-infiltrating lymphocyte (TIL) subpopulations in solid cancers is still debated. Here, we investigated the clinicopathological correlates and prognostic impact of TILs, particularly of γδ T cells, in 162 patients with triple-negative breast cancer (TNBC). A high γδ [...] Read more.
The prognostic impact of the different tumor-infiltrating lymphocyte (TIL) subpopulations in solid cancers is still debated. Here, we investigated the clinicopathological correlates and prognostic impact of TILs, particularly of γδ T cells, in 162 patients with triple-negative breast cancer (TNBC). A high γδ T cell density (>6.625 γδ T cells/mm2) was associated with younger age (p = 0.008), higher tumor histological grade (p = 0.002), adjuvant chemotherapy (p = 0.010), BRCA1 promoter methylation (p = 0.010), TIL density (p < 0.001), and PD-L1 (p < 0.001) and PD-1 expression (p = 0.040). In multivariate analyses, γδ T cell infiltration (cutoff = 6.625 γδ T cells/mm2) was an independent prognostic factor (5-year relapse-free survival: 63.3% vs. 89.8%, p = 0.027; 5-year overall survival: 73.8% vs. 89.9%, p = 0.031, for low vs. high infiltration). This prognostic impact varied according to the tumor PIK3CA mutational status. High γδ T cell infiltration was associated with better survival in patients with PIK3CA wild-type tumors, but the difference was not significant in the subgroup with PIK3CA-mutated tumors. Altogether, these data suggest that high γδ T cell infiltrate is correlated with immune infiltration and might represent a candidate prognostic tool in patients with TNBC. Full article
(This article belongs to the Special Issue Tumor Innate Immune Surveillance)
Show Figures

Figure 1

Back to TopTop